Results with clinical significance.

Providing accurate results and interpretation.

The presence and pattern of gene mutations in a known or suspected hematologic neoplasm can provide critical diagnostic, prognostic, and therapeutic information for physicians. While many hematologic neoplasms show morphologic or phenotypic similarities, most harbor a distinct composition of somatic gene mutations. In addition, many myeloid neoplasms lack a clonal bone marrow cytogenetic finding at diagnosis (normal karyotype) but can be better characterized with the aid of a sufficiently comprehensive gene mutation profile.


At Mayo Clinic Laboratories, we strive to provide the highest quality molecular services available to complement your clinical practice by offering three myeloid gene panels, including a comprehensive 42-gene OncoHeme panel and two acute myeloid leukemia (AML) focused subpanels


Next-Generation Sequencing for Myeloid Malignancies

David Viswanatha, M.D., gives an overview of the next-generation sequencing (NGS) testing for myeloid malignancies available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

Answers for you and your patients.

Our comprehensive NGS panel allows for the evaluation of hematologic neoplasms, specifically of myeloid origin at the time of diagnosis,
disease relapse, or progression. This comprehensive panel can:

  • Aid in diagnostic classification.
  • Provide prognostic and/or therapeutic information for clinical management.
  • Help identify a subset of WHO-recognized possible germline genetic alterations in patients with associated familial predisposition syndromes.

Learn more about how to order these evaluations at your institution.